文献速递肝病消化道肿瘤与早癌

免疫耐受期慢性乙型肝炎的管理

Management of immune-tolerant chronic hepatitis B.
PubMed 文献 · Hepatology · 2025-05-20

本文综述免疫耐受期慢性乙型肝炎的管理。该期以HBV高复制、ALT正常和肝脏炎症轻微为特征,但组织学研究显示部分符合免疫耐受标准者存在显著炎症和纤维化,现有定义可能低估疾病活动度。国际指南多因疗效有限和潜在风险不推荐抗病毒治疗,但部分患者可能从早期干预中获益;本文呼吁重新定义免疫耐受期并开展长期研究以明确治疗对减少纤维化进展和HCC风险的作用。

要点

  • 免疫耐受期以HBV高复制、ALT正常和肝脏炎症轻微为特征。
  • 组织学研究显示部分符合免疫耐受标准者存在显著炎症和纤维化。
  • 国际指南多不推荐抗病毒治疗,但部分患者可能从早期干预中获益。

核心结论

  • 本文强调重新定义免疫耐受期慢性乙型肝炎以纳入病毒学和 histological 参数的重要性,并呼吁开展长期研究以明确治疗在减少纤维化进展和HCC风险中的作用。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 免疫耐受期以HBV高复制、ALT正常和肝脏炎症轻微为特征,但 growing evidence 揭示即使ALT未升高也存在免疫激活、HBV DNA整合和潜在致癌过程。
  • 组织学研究显示符合免疫耐受标准者中可存在显著炎症和纤维化,提示现有定义可能低估疾病活动度。
  • 免疫耐受期治疗仍存争议,国际指南多因疗效有限和潜在风险不推荐抗病毒治疗,但部分免疫耐受患者可能从早期干预中获益。

关键数值与推荐

  • 原文未报告具体数值标准或推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 免疫耐受期治疗的风险与获益尚未完全明确,且缺乏关于治疗阈值的共识使临床决策进一步复杂化。
  • 原文呼吁开展长期研究以明确治疗在减少纤维化进展和HCC风险中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The immune-tolerant (IT) phase of chronic hepatitis B is a distinct stage of infection, characterized by high HBV replication, normal ALT levels, and minimal liver inflammation. Despite its classification as a benign phase, growing evidence challenges this notion, revealing immune activation, HBV DNA integration, and potential oncogenic processes even in the absence of elevated ALT. The IT phase's prolonged high viral replication raises concerns about its implications for HCC risk. Histological studies show that significant inflammation and fibrosis may exist in patients meeting IT criteria, suggesting that the current definitions may underestimate disease activity. Treatment during the IT phase remains controversial, with international guidelines largely recommending against antiviral therapy due to its limited efficacy and potential risks. However, subsets of IT patients may benefit from early intervention. The risks and benefits of therapy in IT chronic hepatitis B are not fully understood, and the lack of consensus regarding treatment thresholds further complicates clinical decision-making. This review highlights the importance of redefining IT chronic hepatitis B to include virological and histological parameters and calls for long-term studies to clarify the role of therapy in reducing fibrosis progression and HCC risk. A more precise understanding of the IT phase is essential to balance the risks of treatment against its potential benefits and to inform future therapeutic strategies.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Kilany MM, Sonneveld MJ, Feld JJ, et al. Management of immune-tolerant chronic hepatitis B. Hepatology. 2025. PMID: 40392125. doi:10.1097/HEP.0000000000001407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。